0001209191-21-010344.txt : 20210212 0001209191-21-010344.hdr.sgml : 20210212 20210212175009 ACCESSION NUMBER: 0001209191-21-010344 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210210 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Markel Stacy CENTRAL INDEX KEY: 0001734780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39351 FILM NUMBER: 21630293 MAIL ADDRESS: STREET 1: RIGEL PHARMACEUTICALS, INC. STREET 2: 1180 VETERANS BLVD., SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvation Bio Inc. CENTRAL INDEX KEY: 0001811063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850862255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 357 TEHAMA STREET, FLOOR 3 CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 754-3517 MAIL ADDRESS: STREET 1: 357 TEHAMA STREET, FLOOR 3 CITY: SAN FRANCISCO STATE: CA ZIP: 94103 FORMER COMPANY: FORMER CONFORMED NAME: Panacea Acquisition Corp DATE OF NAME CHANGE: 20200430 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-10 0 0001811063 Nuvation Bio Inc. NUVB 0001734780 Markel Stacy C/O NUVATION BIO INC. 1500 BROADWAY, SUITE 1401 NEW YORK NY 10036 0 1 0 0 SVP, Human Resources Stock Option (Right to Buy) 4.60 2021-02-10 4 A 0 398935 A 2030-10-04 Class A Common Stock 398935 398935 D Stock Option (Right to Buy) 1.74 2021-02-10 4 A 0 254810 A 2030-01-21 Class A Common Stock 254810 254810 D Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. Options vest as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years. Received in exchange for an option to purchase 254,810 shares of Legacy Nuvation Class A Common Stock. Stacy Markel, by /s/ Ron A. Metzger, Attorney-in-Fact 2021-02-12